Physician profile
Devika H Sood
NPI 1528239696
$3,347.54
in general payments reported to CMS, 2019-2025
26 companies · $574 in 2025
The $574 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $511 · 2021: $416 · 2022: $111 · 2023: $51.96 · 2024: $254 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,268.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $343.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $234.16 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.59 | 2019-2025 | Jardiance |
| Allergan, INC. | $156.28 | 2019-2020 | |
| Medtronic, INC. | $151.94 | 2025 | Minimed 780g |
| Abbott Laboratories | $145.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $109.11 | 2019-2025 | Capvaxive, Rotateq, Vaxelis |
| Lifescan, INC. | $108.54 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $102.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $102.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.21 | 2019-2020 | |
| Exact Sciences Corporation | $63.92 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $62.52 | 2019-2025 | Trelegy Ellipta |
| Shire North American Group INC | $37.19 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $31.88 | 2024-2025 | Rexulti |
| Abbvie INC. | $27.58 | 2022 | |
| Pfizer INC. | $25.22 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $24.24 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $22.17 | 2025 | Auvelity |
| Genentech USA, INC. | $22.17 | 2019 | |
| Amgen INC. | $18.79 | 2024 | Repatha, Otezla |
| Sanofi Pasteur INC. | $16.70 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.34 | 2020 | |
| Ibsa Pharma INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devika Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.